Join EY, McDermott Will & Schulte, and other top industry leaders for a lively program featuring diverse voices in the sector and investor community as they discuss industry trends, innovation, regulatory change and the sector outlook in 2026.
January 13, 2026 - Program overview
Cross-border biopharma: How pricing, policy and geopolitics are shaping 2026’s deal landscape
8:30 AM – 9:10 AM
Co-moderators: Ranu Carroll - EY-Parthenon Americas Life Sciences Leader | McDermott Will & Schulte
As global headwinds multiply, biopharma dealmaking faces a new reality — one where pricing reforms, tax pressure and shifting geopolitical alliances are increasingly driving strategy. This panel brings together US and EU leaders to unpack how policy trends and market sentiment are shaping deal flow and investment priorities across the globe. Expect a clear-eyed discussion of how companies are recalibrating transaction strategy, where capital is moving next and what 2026’s regulatory and political landscape could mean for cross-border growth.
Medtech M&A: Will 2026 finally be a breakout year?
9:10 AM – 9:50 AM
Moderator: John Babitt – EY Global MedTech Leader | McDermott Will & Schulte
The MedTech industry is entering a pivotal period of portfolio reshaping, marked by continued M&A momentum for certain industry participants and selective public-market re-openings. This panel will explore key trends shaping the sector—from the evolution of MedTech deal activity over the past decade to the current state of the IPO market and the growing role of private equity in fueling innovation and take privates. The discussion will highlight recent portfolio optimization moves as many companies continue to reposition themselves to take advantage of higher-growth end markets. Panelists will share perspectives on valuation dynamics, deal timing, and the strategic rationale driving both corporate and sponsor-led transactions, offering practical insights into where MedTech dealmaking is headed next.
Fireside chat: Innovative capital strategies in life sciences
10:05 AM – 10:35 AM
Co-moderators: Arda Ural - EY Americas Life Sciences Leader | McDermott Will & Schulte
As the life sciences sector enters a new phase of growth, capital strategies are rapidly evolving to meet new market demands. This session will explore the innovative approaches shaping the industry, and the strategic investment priorities expected to define the landscape in 2026.
Beyond compliance: How regulation is reshaping health and life sciences investments
10:35 AM – 11:15 AM
Co-moderators: Heather Meade - Principal, Washington Council, Ernst & Young LLP | McDermott Will & Schulte
Political uncertainty, shifting Food and Drug Administration (FDA) priorities and evolving global trade dynamics are increasingly dictating where and how capital flows into healthcare and life sciences. From approval timelines and supply chain resilience to funding disruptions and policy reform, regulation now sits at the center of investment and growth strategy. This panel will examine how investors and operators are underwriting regulatory risk, finding opportunities amid policy volatility and recalibrating deal theses for a more complex market. Expect an unvarnished discussion of how evolving FDA and global policy trends are driving valuations, deal pacing and innovation across the sector.
Health innovations: Creating connected, member-focused care networks
11:15 AM – 11:45 AM
Co-moderators: Deblina Ghosh - Principal, Strategy and Execution, EY-Parthenon | McDermott Will & Schulte
Stakeholders grappling with rising healthcare costs are turning to technology and new models for delivering and managing care. From breakthroughs in the pharmacy value chain to centers of excellence (COEs) and artificial intelligence (AI) solutions that enhance provider efficiency, organizations are leveraging technology to engage members and contain costs. This session will explore how emerging platforms — such as AI-powered scheduling and documentation tools and more — are driving a more connected, member-focused network of care. Join us to examine the evolving role of pharmacy, providers and AI in building the healthcare network of the future.
Fireside chat: Private equity (PE) investment trends in healthcare
11:45 AM – 12:15 PM
Co-moderators: Dan Shoenholz - EY-Parthenon Health and Life Sciences Private Equity Leader | McDermott Will & Schulte
As we enter the New Year, our professional panel will explore the evolving outlook for healthcare PE investing, highlighting the themes that present the most promising opportunities for investors. In this session, attendees will gain valuable insights into the key trends and challenges shaping the healthcare investment landscape. Whether you’re a seasoned investor or new to the industry, this fireside chat will provide you with actionable insights and a deeper understanding of the forces driving activity in healthcare PE.